Active	Status	Sponsor type	Region	Phase	Filter
5 Active 40 Inactive 45 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Targretin oral (bexarotene oral) / ReXceptor
2014-003145-99: A trial to determine bexarotene's safety and tolerability and it's ability to promote brain repair in patients with multiple sclerosis.	Ongoing	2	50	Europe	Bexarotene, Capsule, hard, Targretin	Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge	Relapsing-remitting multiple sclerosis already on interferon-beta therapy, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
ACTRN12613000465752: Apolipoprotein E driven therapeutics for Alzheimer’s disease	Not yet recruiting	1	20			Nuclear Medicine and Centre for PET Research Fund, Nuclear Medicine and Centre for Positron Emission Tomography (PET ) Research Fund	Alzheimer's Disease
NCT00206479: U19 Project 1 (Targretin Effect on Breast Cancer)	Active, not recruiting	1	30	US	Targretin, tagretin	Baylor Breast Care Center, National Institutes of Health (NIH)	Breast Cancer	01/12	01/12
NCT05296304: A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides	Recruiting	1	20	US	Bexarotene, Targretin®, Total Skin Electron Beam (TSEB)	Memorial Sloan Kettering Cancer Center	Cutaneous T-cell Lymphoma	03/25	03/25
NCT04664829: The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC	Recruiting	1	12	RoW	Bexarotene, Targretin, Capecitabine, Xeloda	National Cancer Centre, Singapore, National Medical Research Council (NMRC), Singapore	Metastatic Triple-Negative Breast Carcinoma	09/24	09/25